ReviewTherapeutic advances in infectious disease
Mpox: transmission dynamics, treatment, and innovations.
Review in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The resurgence of monkeypox (mpox), driven by Clade IIb of the monkeypox virus (MPXV), has intensified global concerns about its transmission, treatment, and prevention. Mpox, a zoonotic orthopoxvirus and is primarily transmitted through close contact with infected individuals, contaminated surfaces, or respiratory droplets. Historically, the virus has been divided into two clades: Clade I, endemic to Central Africa and characterized by higher fatality rates, and Clade II, linked to milder disease in West Africa. The unprecedented global spread of Clade IIb Mpox in 2022, affecting over 99,000 individuals across 118 countries, underscored the potential for widespread transmission beyond endemic regions. This review provides a detailed examination of the transmission dynamics of mpox, current treatments, innovations, and global health challenges. Current treatment strategies primarily involve supportive care, with advanced therapeutics such as tecovirimat, cidofovir, and brincidofovir reserved for severe cases. While these antivirals show promise, their clinical efficacy and safety remain inadequately substantiated, creating a pressing need for rigorous trials. Preventive measures, including vaccination and postexposure prophylaxis, remain pivotal in mitigating disease spread, yet face barriers such as limited supply, accessibility, and vaccine hesitancy. Emerging therapeutic innovations, such as monoclonal antibodies, gene-editing technologies, and RNA-based therapies, offer hope for addressing these gaps. These novel approaches aim to enhance treatment specificity, minimize off-target effects, and reduce the risk of resistance. However, their successful integration into clinical practice demands robust validation through preclinical and clinical research. In addressing the challenges ahead, this review underscores the critical importance of global collaboration to strengthen epidemiological surveillance, accelerate drug development, and optimize prevention strategies. The emergence of drug-resistant strains, the persistence of mpox in vulnerable populations, and the potential for future outbreaks necessitate sustained investment in research and public health infrastructure. By integrating innovative therapeutic approaches, effective preventive measures, and comprehensive outbreak management strategies, the global health community can better address the ongoing threat of mpox and prepare for future public health challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.